Johnson & Johnson 0R34
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 0R34 is a good fit for your portfolio.
News
-
Xencor: J&J's Janssen Termintates Rights to Plamotamab
-
Johnson and Johnson Talcum-Settlement Consent Judgments Filed — Update
-
J&J Talcum-Settlement Consent Judgments Filed, U.S. State AGs Say
-
J&J to Acquire Skin Disease Treatment Rights from Numab in $1.25 Billion Deal
-
Johnson & Johnson On Track for Largest Percent Decrease Since August 2023 — Data Talk
-
J&J-Linked Rapport Therapeutics Files For IPO
-
Johnson & Johnson Strikes $850 Million Deal to Boost Dermatology Portfolio
-
J&J scores lowest spread of year on bonds to help fund $13 billion bid for Shockwave
Trading Information
- Previous Close Price
- $145.20
- Day Range
- $144.51–145.80
- 52-Week Range
- $143.59–155.00
- Bid/Ask
- $0.00 / $0.00
- Market Cap
- $349.69 Bil
- Volume/Avg
- 11,572 / 12,202
Key Statistics
- Price/Earnings (Normalized)
- 14.01
- Price/Sales
- 4.11
- Dividend Yield (Trailing)
- 3.28%
- Dividend Yield (Forward)
- 3.38%
- Total Yield
- 3.28%
Company Profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Value
- Total Number of Employees
- 134,400
- Website
- https://www.jnj.com
Competitors
Valuation
|
Metric
|
0R34
|
LLY
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.01 | 93.94 | 59.67 |
Price/Book Value | 5.04 | 65.16 | 8.12 |
Price/Sales | 4.11 | 22.09 | 5.37 |
Price/Cash Flow | 15.84 | 91.79 | 18.88 |
Price/Earnings
0R34
LLY
MRK
Financial Strength
|
Metric
|
0R34
|
LLY
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.84 | 0.68 | 0.68 |
Current Ratio | 1.17 | 1.35 | 1.25 |
Interest Coverage | 23.57 | 14.11 | 3.97 |
Quick Ratio
0R34
LLY
MRK
Profitability
|
Metric
|
0R34
|
LLY
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 12.64% | 11.20% | 5.22% |
Return on Equity (Normalized) | 31.72% | 57.69% | 13.56% |
Return on Invested Capital (Normalized) | 20.11% | 20.65% | 8.29% |
Return on Assets
0R34
LLY
MRK
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Wwttwylc | Wrljb | $834.9 Bil | |||
| Johnson & Johnson
JNJ
| Rqdzfzhsh | Wvsw | $350.3 Bil | |||
| Merck & Co Inc
MRK
| Trygrwsm | Nnjp | $327.9 Bil | |||
| AbbVie Inc
ABBV
| Cjzjnwnt | Fxw | $297.7 Bil | |||
| AstraZeneca PLC ADR
AZN
| Gcrscsjwd | Xbsp | $247.3 Bil | |||
| Roche Holding AG ADR
RHHBY
| Pfnqdhzjf | Hfxh | $223.9 Bil | |||
| Novartis AG ADR
NVS
| Ptnchncx | Tmk | $216.8 Bil | |||
| Amgen Inc
AMGN
| Lzmbgzhwv | Mbyc | $160.2 Bil | |||
| Pfizer Inc
PFE
| Jbzyfkk | Mfgf | $156.0 Bil | |||
| Sanofi SA ADR
SNY
| Gzgdpbzrm | Pzdb | $116.1 Bil |